Title: Diuretic effects of sodium–glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure
Abstract: The prevalence of type 2 diabetes mellitus (T2DM) in the heart failure (HF) population is 15% to 25% [ 1 Zannad F. Braincon S. Juilliere Y. Mertes P.M. Villemot J.P. Alla F. Virion J.M. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. J. Am. Coll. Cardiol. 1999; 33: 734-742 Abstract Full Text Full Text PDF PubMed Scopus (296) Google Scholar , 2 Christophe B. Nicolas L. Eugène P. Mc F. Van Belle Eric Alain M. Pascal de G. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc. Diabetol. 2003; 2: 1 Crossref PubMed Scopus (152) Google Scholar ], and T2DM plays an important role in the pathogenesis, prognosis, and response to treatment of HF [ [3] Solang L. Malmberg K. Ryden L. Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur. Heart J. 1999; 20: 789-795 Crossref PubMed Scopus (166) Google Scholar ]. Loop diuretics are prescribed to the vast majority of patients with symptomatic HF, but they directly upregulate renin gene expression by blocking sodium chloride uptake at the macula densa, which activates the renin–angiotensin–aldosterone system (RAAS) and the sympathetic nervous system (SNS), both of which are known to have adverse effects in heart failure [ 4 Francis G.S. Benedict C. Johnstone D.E. Kirlin P.C. Nicklas J. Liang C.S. Kubo S.H. Rudintoretsky E. Yusuf S. Comparison of neuroendocrine activation in patients with left-ventricular dysfunction with and without congestive-heart-failure — a substudy of the studies of left-ventricular dysfunction (SOLVD). Circulation. 1990; 82: 1724-1729 Crossref PubMed Scopus (1293) Google Scholar , 5 Bayliss J. Norell M. Canepaanson R. Sutton G. Poolewilson P. Untreated Heart-failure — clinical and neuroendocrine effects of introducing diuretics. Br. Heart J. 1987; 57: 17-22 Crossref PubMed Scopus (422) Google Scholar , 6 Dohi K. Ito M. Novel diuretic strategies for the treatment of heart failure in Japan. Circ. J. 2014; 78: 1816-1823 Crossref PubMed Scopus (28) Google Scholar ]. Recently, a new class of oral glucose-lowering agents that inhibit renal sodium–glucose cotransporter 2 (SGLT2) has been approved. SGLT2 is present in the brush border of epithelial cells in the S1 and S2 segments of proximal renal tubules. Inhibition of SGLT2 leads to reduced glucose and sodium reabsorption in the proximal tubule [ 7 Lambers Heerspink H.J. de Zeeuw D. Wie L. Leslie B. List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metab. 2013; 15: 853-862 Crossref PubMed Scopus (573) Google Scholar , 8 Oliva Raymond V. Bakris George L. Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors. J. Am. Soc. Hypertens. 2014; 8: 330-339 Abstract Full Text Full Text PDF PubMed Scopus (168) Google Scholar ], which has the potential for a diuretic effect without stimulating RAAS and SNS activation via the macula densa mechanism. Therefore, the aim of this study was to assess the short-term diuretic effects of ipragliflozin, an oral SGLT2 inhibitor, and their influences on neurohumoral activation in patients with T2DM and HF. Corrigendum to "Diuretic effects of sodium–glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure" [Int. J. Cardiol. 201 (Jul 31 2015) 1–3]International Journal of CardiologyVol. 206PreviewThe authors regret several errors in the main text, Fig. 1 and figure legend of our article entitled "Diuretic Effects of Sodium–Glucose Cotransporter 2 Inhibitor in Patients with Type 2 Diabetes Mellitus and Heart Failure" in the International Journal of Cardiology (Int J Cardiol. 2015 Jul. 31;201:1–3). Full-Text PDF
Publication Year: 2015
Publication Date: 2015-12-01
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 31
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot